Repare Capex To Revenue from 2010 to 2024

RPTX Stock  USD 3.32  0.17  5.40%   
Repare Therapeutics Capex To Revenue yearly trend continues to be fairly stable with very little volatility. Capex To Revenue will likely drop to 0.04 in 2024. Capex To Revenue is the ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets. View All Fundamentals
 
Capex To Revenue  
First Reported
2010-12-31
Previous Quarter
0.03790116
Current Value
0.036
Quarterly Volatility
7.55059725
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Repare Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Repare Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 2.8 M, Interest Income of 13.8 M or Depreciation And Amortization of 1.8 M, as well as many indicators such as Price To Sales Ratio of 5.71, Dividend Yield of 0.0 or PTB Ratio of 1.52. Repare financial statements analysis is a perfect complement when working with Repare Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Repare Therapeutics Correlation against competitors.
For more information on how to buy Repare Stock please use our How to Invest in Repare Therapeutics guide.

Latest Repare Therapeutics' Capex To Revenue Growth Pattern

Below is the plot of the Capex To Revenue of Repare Therapeutics over the last few years. It is the ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets. Repare Therapeutics' Capex To Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Repare Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Capex To Revenue10 Years Trend
Slightly volatile
   Capex To Revenue   
       Timeline  

Repare Capex To Revenue Regression Statistics

Arithmetic Mean12.17
Geometric Mean3.19
Coefficient Of Variation62.03
Mean Deviation6.45
Median16.57
Standard Deviation7.55
Sample Variance57.01
Range16.5658
R-Value(0.77)
Mean Square Error25.17
R-Squared0.59
Significance0.0008
Slope(1.30)
Total Sum of Squares798.16

Repare Capex To Revenue History

2024 0.036
2023 0.0379
2022 0.004566
2021 0.22

About Repare Therapeutics Financial Statements

Repare Therapeutics investors use historical fundamental indicators, such as Repare Therapeutics' Capex To Revenue, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Repare Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Capex To Revenue 0.04  0.04 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Repare Stock Analysis

When running Repare Therapeutics' price analysis, check to measure Repare Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Repare Therapeutics is operating at the current time. Most of Repare Therapeutics' value examination focuses on studying past and present price action to predict the probability of Repare Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Repare Therapeutics' price. Additionally, you may evaluate how the addition of Repare Therapeutics to your portfolios can decrease your overall portfolio volatility.